A pharma exec raised the price of antibiotic by 400 percent — and the government can’t do much about image

Stat Plus, September 11, 2018
Ike Swetlitz and Nicholas Florko, quoting Rachel Sachs (Academic Fellow Alumnus)


Read the full article

From the article: 

Three years after Martin Shkreli became the poster boy of pharmaceutical company greed, another drug company executive is setting himself up for a similar infamy. And now, just as then, there is little the government can do — besides make a fuss.

Nirmal Mulye, CEO of Nostrum Laboratories, quadrupled the price of a generic liquid antibiotic used to treat bladder infections, the Financial Times reportedTuesday. And he had little shame.

“I think it is a moral requirement to make money when you can … to sell the product for the highest price,” Mulye told the FT.

Read more here!

health law policy pharmaceuticals